EsteeLauder (EL) Q4 2025 earnings review
Turnaround Begins: FY26 Guidance Signals Growth After Three Years of Decline
Estée Lauder closed a difficult fiscal 2025 with organic sales declining 8% and adjusted EPS falling 42%, marking the third consecutive year of negative growth. The performance was dragged down by a 28% collapse in the high-margin Asia Travel Retail business and softness in mainland China. However, the focus has squarely shifted to the FY26 outlook, which signals a bottoming process. Management guides for a return to modest organic sales growth (0-3%) and a significant rebound in adjusted EPS (+26-39%). The company's massive 'Profit Recovery & Growth Plan' (PRGP) is the key driver, delivering 230 bps of gross margin expansion in FY25 despite the sales drop. While the turnaround is underway, the recovery is slow and faces new headwinds, including a projected $100 million tariff impact.
🐂 Bull Case
FY26 guidance for sales, margin, and EPS growth marks the first positive annual outlook after three years of declines, signaling the strategic pivot is beginning to yield results.
The massive restructuring plan is working. Gross margin expanded by 230 basis points in FY25 despite severe sales deleverage, providing a crucial profit cushion for the recovery.
The company gained market share in the U.S. and mainland China during the second half of FY25, suggesting that key brands are regaining traction with consumers in critical geographies.
🐻 Bear Case
The FY26 organic growth guidance of 0-3% is tepid and barely keeps pace with projected global prestige beauty market growth of 2-3%, indicating a lack of strong top-line momentum.
While the company is reducing its exposure, the highly profitable Travel Retail channel remains volatile. The recovery hinges on a rebound in this channel, where consumer conversion remains weak.
An estimated $100 million negative impact on profitability from new tariffs in FY26 creates an external pressure that could threaten the fragile margin recovery.
⚖️ Verdict: ⚪
Mixed. The company has successfully set a low bar and is showing clear signs of a reversal. The PRGP is providing a strong profitability cushion and the worst appears to be over. However, the top-line recovery is fragile and barely positive, while new macro risks loom. A return to strong, profitable growth is not yet secured, making the story one of cautious optimism.
Key Themes
PRGP Restructuring Fuels Margin Recovery
The Profit Recovery and Growth Plan (PRGP) is the engine of the turnaround. It successfully delivered 230 basis points of gross margin expansion in FY25 despite an 8% sales decline. For FY26, cost savings from this plan are the primary driver of the guided 140-190 basis point expansion in adjusted operating margin. The program includes a net reduction of 5,800 to 7,000 positions, outsourcing initiatives, and procurement savings, which will fund reinvestment in brands.
Core Skin Care Segment Is a Major Laggard
A significant red flag is the performance of the Skin Care division, the company's largest segment. Organic sales fell 12% in FY25, substantially underperforming the company average of -8%. This weakness in core franchises like Estée Lauder and La Mer, driven by the Asia travel retail collapse, contradicts the positive narrative on brand health and poses a risk to the quality of the overall recovery.
Aggressive Expansion into New Channels
A key strategic shift is the aggressive push into high-growth online channels. The company has launched 11 brands in Amazon's U.S. Premium Beauty store and is expanding to Amazon in the U.K. and Mexico. This pivot helped accelerate online organic sales growth to mid-single digits in H2 FY25, with online reaching a record 31% of total sales, providing a vital channel for new consumer acquisition.
Asia Travel Retail Remains a Drag
Global Travel Retail (GTR), historically a profit engine, saw organic sales collapse by 28% in FY25. While management is strategically reducing exposure (GTR is now 15% of sales vs. a ~29% peak), the business remains volatile. The FY26 guidance for a 'modest' return to growth is off a severely depressed base and hinges on improving consumer conversion, which remains weak.
Innovation Pipeline Accelerating
Under new leadership, the company is focused on speeding up its innovation cycle. Management is targeting innovation to represent over 25% of sales in FY26 and aims to triple the percentage of new products launched in under a year. Key focus areas include night treatments, longevity science in skincare, and luxury fragrance, aiming to better capture fast-moving industry trends.
New Tariff Headwind Emerges for FY26
Management has quantified a new profitability headwind of approximately $100 million for fiscal 2026 due to recently enacted tariffs, net of mitigation efforts. This external pressure adds risk to the company's margin recovery targets and may limit flexibility for reinvestment.
Value Destruction from Past M&A
The company recorded massive impairment charges of $1.286 billion in FY25 related to brands like Dr.Jart+, Too Faced, and TOM FORD. These write-downs are a direct admission that past acquisitions have significantly underperformed expectations, resulting in a substantial destruction of shareholder value.
Other KPIs
Down 42% YoY from $2.59 in FY24. This result caps a multi-year earnings decline driven by sales pressure in high-margin Asia-related businesses and significant restructuring charges. The FY26 guidance for $1.90-$2.10 implies a sharp reversal.
A key bright spot, expanding 230 basis points from 71.7% in FY24. This improvement, driven by PRGP efficiencies and lower obsolescence, occurred despite an 8% organic sales decline, demonstrating strong cost control and providing the foundation for the FY26 profit recovery.
Down from $1.27B in FY25 and $2.36B in FY24. The outlook indicates cash generation will remain constrained during the turnaround, pressured by lower earnings (compared to prior years) and peak restructuring-related payments. A recovery in cash flow is expected to lag the earnings rebound.
Guidance
Reversing. After a decline of 8% in FY25 and 13% in Q4, this guidance signals a critical pivot back to growth. The modest rate reflects a bottoming-out of declines in Asia Travel Retail and mainland China, combined with continued momentum in the Americas.
Reversing. An expected expansion of 140-190 basis points from 8.0% in FY25. This recovery is almost entirely driven by PRGP cost savings, as the muted top-line growth provides minimal operating leverage.
Reversing. A guided rebound of 26% to 39% from FY25's depressed base of $1.51. The growth is primarily a function of the anticipated operating margin recovery and assumes no further major one-time charges.
The guidance assumes a return to 'mid-single-digit' organic growth in mainland China and 'modest growth' in the global travel retail business. This implies the two largest drags on FY25 results are expected to become net contributors in FY26.